279 related articles for article (PubMed ID: 19885810)
21. The UK Sport perspective on detecting growth hormone abuse.
Stow MR; Wojek N; Marshall J
Growth Horm IGF Res; 2009 Aug; 19(4):375-7. PubMed ID: 19487144
[TBL] [Abstract][Full Text] [Related]
22. [Identification of candidate genes and expression profiles, as doping biomarkers].
Paparini A; Impagnatiello F; Pistilli A; Rinaldi M; Gianfranceschi G; Signori E; Stabile AM; Fazio V; Rende M; Romano Spica V
Ann Ig; 2007; 19(4):303-14. PubMed ID: 17937323
[TBL] [Abstract][Full Text] [Related]
23. Application of the Athlete Biological Passport Approach to the Detection of Growth Hormone Doping.
Equey T; Pastor A; de la Torre Fornell R; Thomas A; Giraud S; Thevis M; Kuuranne T; Baume N; Barroso O; Aikin R
J Clin Endocrinol Metab; 2022 Feb; 107(3):649-659. PubMed ID: 34726230
[TBL] [Abstract][Full Text] [Related]
24. Beyond reasonable doubt: catching the growth hormone cheats.
Holt RI
Pediatr Endocrinol Rev; 2007 Mar; 4(3):228-32. PubMed ID: 17551486
[TBL] [Abstract][Full Text] [Related]
25. Responses of the growth hormone (GH) and insulin-like growth factor axis to exercise, GH administration, and GH withdrawal in trained adult males: a potential test for GH abuse in sport.
Wallace JD; Cuneo RC; Baxter R; Orskov H; Keay N; Pentecost C; Dall R; Rosén T; Jørgensen JO; Cittadini A; Longobardi S; Sacca L; Christiansen JS; Bengtsson BA; Sönksen PH
J Clin Endocrinol Metab; 1999 Oct; 84(10):3591-601. PubMed ID: 10523001
[TBL] [Abstract][Full Text] [Related]
26. Immunoassays for the measurement of IGF-II, IGFBP-2 and -3, and ICTP as indirect biomarkers of recombinant human growth hormone misuse in sport. Values in selected population of athletes.
Abellan R; Ventura R; Palmi I; di Carlo S; Bacosi A; Bellver M; Olive R; Pascual JA; Pacifici R; Segura J; Zuccaro P; Pichini S
J Pharm Biomed Anal; 2008 Nov; 48(3):844-52. PubMed ID: 18617352
[TBL] [Abstract][Full Text] [Related]
27. Biochemical markers of insulin-like growth factor-I misuse in athletes: the response of serum IGF-I, procollagen type III amino-terminal propeptide, and the GH-2000 score to the administration of rhIGF-I/rhIGF binding protein-3 complex.
Guha N; Erotokritou-Mulligan I; Bartlett C; Nevitt SP; Francis M; Bassett EE; Cowan DA; Sönksen PH; Holt RI
J Clin Endocrinol Metab; 2014 Jun; 99(6):2259-68. PubMed ID: 24606087
[TBL] [Abstract][Full Text] [Related]
28. New detection methods of growth hormone and growth factors.
Bidlingmaier M
Endocr Dev; 2012; 23():52-9. PubMed ID: 23182820
[TBL] [Abstract][Full Text] [Related]
29. Growth factors, muscle function, and doping.
Goldspink G; Wessner B; Tschan H; Bachl N
Endocrinol Metab Clin North Am; 2010 Mar; 39(1):169-81, xi. PubMed ID: 20122457
[TBL] [Abstract][Full Text] [Related]
30. Effectiveness of GH isoform differential immunoassay for detecting rhGH doping on application of various growth factors.
Okano M; Nishitani Y; Sato M; Kageyama S
Drug Test Anal; 2012 Sep; 4(9):692-700. PubMed ID: 22733714
[TBL] [Abstract][Full Text] [Related]
31. Genetic and protein biomarkers in blood for the improved detection of GH abuse.
Ferro P; Ventura R; Pérez-Mañá C; Farré M; Segura J
J Pharm Biomed Anal; 2016 Sep; 128():111-118. PubMed ID: 27243825
[TBL] [Abstract][Full Text] [Related]
32. Overview of the legal framework applicable to the marker method for the detection of human growth hormone.
Young RR; Bielak JS; Horvitz SL
Growth Horm IGF Res; 2009 Aug; 19(4):366-8. PubMed ID: 19608446
[TBL] [Abstract][Full Text] [Related]
33. The effect of a period of intense exercise on the marker approach to detect growth hormone doping in sports.
Voss SC; Robinson N; Alsayrafi M; Bourdon PC; Schumacher YO; Saugy M; Giraud S
Drug Test Anal; 2014 Jun; 6(6):582-6. PubMed ID: 24827554
[TBL] [Abstract][Full Text] [Related]
34. The history of doping and growth hormone abuse in sport.
Holt RI; Erotokritou-Mulligan I; Sönksen PH
Growth Horm IGF Res; 2009 Aug; 19(4):320-6. PubMed ID: 19467612
[TBL] [Abstract][Full Text] [Related]
35. Indirect markers for detecting growth hormone abuse by athletes.
Banfi G; Colombini A; Lombardi G
Clin Endocrinol (Oxf); 2010 Aug; 73(2):272-3; author reply 274-5. PubMed ID: 20201950
[No Abstract] [Full Text] [Related]
36. The effects of a freeze-thaw cycle and pre-analytical storage temperature on the stability of insulin-like growth factor-I and pro-collagen type III N-terminal propeptide concentrations: Implications for the detection of growth hormone misuse in athletes.
Guha N; Erotokritou-Mulligan I; Bartlett C; Cowan DA; Bassett EE; Stow M; Sönksen PH; Holt RI
Drug Test Anal; 2012 Jun; 4(6):455-9. PubMed ID: 22511534
[TBL] [Abstract][Full Text] [Related]
37. Growth hormone administration: is it safe and effective for athletic performance.
Birzniece V; Nelson AE; Ho KK
Endocrinol Metab Clin North Am; 2010 Mar; 39(1):11-23, vii. PubMed ID: 20122446
[TBL] [Abstract][Full Text] [Related]
38. Growth hormone and the adolescent athlete: What are the data for its safety and efficacy as an ergogenic agent?
Rogol AD
Growth Horm IGF Res; 2009 Aug; 19(4):294-9. PubMed ID: 19487146
[TBL] [Abstract][Full Text] [Related]
39. The development of decision limits for the implementation of the GH-2000 detection methodology using current commercial insulin-like growth factor-I and amino-terminal pro-peptide of type III collagen assays.
Erotokritou-Mulligan I; Guha N; Stow M; Bassett EE; Bartlett C; Cowan DA; Sönksen PH; Holt RI
Growth Horm IGF Res; 2012 Apr; 22(2):53-8. PubMed ID: 22305721
[TBL] [Abstract][Full Text] [Related]
40. Doping, gene transfer and sport.
Verma IM
Mol Ther; 2004 Sep; 10(3):405. PubMed ID: 15336640
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
